Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells
Authors:
Open Access
- 1 September 2011
- journal article
- retracted article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 6, 1963-1975
Abstract
Thiolated chitosan has high transfection and mucoadhesive properties. We investigated the potential of two recently synthesized polymers: NAC-C (N-acetyl cysteine-chitosan) and NAP-C (N-acetyl penicillamine-chitosan) in anticancer drug delivery targeting epidermal growth factor receptor (EGFR). Doxorubicin (DOX) and antisense oligonucleotide (ASOND)-loaded polymer nanoparticles were prepared in water by a gelation process. Particle characterization, drug loading, and drug release were evaluated. To verify drug delivery efficiency in vitro experiments on a breast cancer cell line (T47D) were performed. EGFR gene and protein expression was analyzed by real time quantitative polymerase chain reaction and Western blotting, respectively. A loading percentage of 63% ± 5% for ASOND and 70% ± 5% for DOX was achieved. Drug release data after 15 hours showed that ASOND and DOX were completely released from chitosan-based particles while a lower and more sustained release of only 22% ± 8% was measured for thiolated particles. In a cytosol simulated release medium/reducing environment, such as found intracellularly, polymer-based nanoparticles dissociated, liberating approximately 50% of both active substances within 7 hours. ASOND-loaded polymer nanoparticles had higher stability and high mucoadhesive properties. The ASOND-loaded thiolated particles significantly suppressed EGFR gene expression in T47D cells compared with ASOND-loaded chitosan particles and downregulated EGFR protein expression in cells. This study could facilitate future investigations into the functionality of NAP-C and NAC-C polymers as an efficient ASOND delivery system in vitro and in vivo.Keywords
This publication has 21 references indexed in Scilit:
- Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vectorInternational Journal of Nanomedicine, 2010
- Thiolated Chitosan Nanoparticles as an Oral Delivery System for Amikacin: In Vitro and Ex Vivo EvaluationsJournal of Nanoscience and Nanotechnology, 2009
- Growth and EGFR Regulation in Breast Cancer Cells by Vitamin D and Retinoid CompoundsBreast Cancer Research and Treatment, 2004
- Polymer‐coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reductionThe Journal of Gene Medicine, 2004
- Strategies to Improve DNA Polyplexes for in Vivo Gene Transfer: Will “Artificial Viruses” Be the Answer?Pharmaceutical Research, 2004
- Non-viral gene therapy: polycation-mediated DNA deliveryApplied Microbiology and Biotechnology, 2003
- Biodegradable nanoparticles for drug and gene delivery to cells and tissueAdvanced Drug Delivery Reviews, 2003
- Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivoJournal of Pharmacy and Pharmacology, 2002
- Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growthJournal of Cellular Biochemistry, 2001
- Two problems in antisense biotechnology: in vitro delivery and the design of antisense experimentsBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1999